SPRB Spruce Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SPRB

Price (delayed)

$53.89

Market cap

$148.32M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$36.6

Enterprise value

$101.04M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 8

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control ...

Highlights
SPRB's EPS has surged by 63% year-on-year and by 28% since the previous quarter
The net income has grown by 33% year-on-year and by 4.6% since the previous quarter
The company's quick ratio has surged by 180% YoY but it fell by 5% QoQ
The company's equity has surged by 126% YoY but it fell by 19% QoQ
The revenue has plunged by 100% YoY
SPRB's gross profit has shrunk by 100% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.sprucebiosciences.com
Peers: AMGN GILD VRTX REGN

Key stats

What are the main financial stats of SPRB

SPRB stock price

How has the Spruce Biosciences stock price performed over time
Intraday
9.87%
1 week
9.55%
1 month
-9.23%
1 year
1,092.26%
YTD
-38.14%
QTD
-17.54%

Financial performance

How have Spruce Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$34.01M
Net income
-$37.19M
Gross margin
N/A
Net margin
N/A
The revenue has plunged by 100% YoY
SPRB's gross profit has shrunk by 100% YoY
Spruce Biosciences's operating income has increased by 41% YoY and by 7% from the previous quarter
The net income has grown by 33% year-on-year and by 4.6% since the previous quarter

Price vs fundamentals

How does SPRB's price correlate with its fundamentals

Growth

What is Spruce Biosciences's growth rate over time

Valuation

What is Spruce Biosciences stock price valuation
P/E
N/A
P/B
2.13
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
SPRB's EPS has surged by 63% year-on-year and by 28% since the previous quarter
The company's equity has surged by 126% YoY but it fell by 19% QoQ
The stock's price to book (P/B) is 116% more than its 5-year quarterly average of 0.9 and 29% more than its last 4 quarters average of 1.5
The revenue has plunged by 100% YoY

Efficiency

How efficient is Spruce Biosciences business performance
The return on equity is up by 24% since the previous quarter but it has declined by 9% year-on-year
The return on assets is up by 21% since the previous quarter

Dividends

What is SPRB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SPRB.

Financial health

How did Spruce Biosciences financials performed over time
SPRB's total assets is 161% greater than its total liabilities
The company's quick ratio has surged by 180% YoY but it fell by 5% QoQ
SPRB's current ratio has surged by 139% year-on-year but it is down by 10% since the previous quarter
The company's debt is 80% lower than its equity
The company's equity has surged by 126% YoY but it fell by 19% QoQ
Spruce Biosciences's debt to equity has surged by 54% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.